Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma

Leuk Lymphoma. 2015 Apr;56(4):1123-5. doi: 10.3109/10428194.2014.921298. Epub 2014 Jul 15.

Authors

Kaori Ito¹, Masataka Okamoto, Maiko Ando, Yukiko Kakumae, Akinao Okamoto, Yoko Inaguma, Masutaka Tokuda, Masamitsu Yanada, Shigeki Yamada, Nobuhiko Emi

Affiliation

¹ Department of Pharmacy, Fujita Health University Hospital , Toyoake , Japan.

PMID: 24828861
DOI: 10.3109/10428194.2014.921298

No abstract available

Publication types

Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride / administration & dosage
CD4-CD8 Ratio
CD4-Positive T-Lymphocytes / drug effects
CD8-Positive T-Lymphocytes / drug effects
Drug Resistance, Neoplasm
Female
Humans
Immune System / drug effects*
Lymphocyte Count
Lymphoma, Follicular / drug therapy*
Lymphoma, Follicular / immunology
Lymphoma, Follicular / pathology
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / immunology
Lymphoma, Mantle-Cell / pathology
Male
Middle Aged
Recurrence
Retrospective Studies
Rituximab / administration & dosage
Treatment Outcome

Substances

Rituximab
Bendamustine Hydrochloride